Jun 24, 2022 7:00am EDT Can-Fite’s CF602 Reverses Erectile Dysfunction in Diabetic Pre-clinical Model: Study Published in Peer-Reviewed Journal Andrologia
Jun 09, 2022 7:00am EDT Can-Fite Announces Publication of Clinical Study Data for Piclidenoson and Namodenoson in Scientific Journal
May 26, 2022 7:00am EDT Can-Fite Reports First Quarter 2022 Financial Results & Provides Clinical Update
May 02, 2022 7:00am EDT Can-Fite’s CEO to Present Namodenoson’s Efficacy in Liver Cancer as Expert Speaker at the Adenosine Pathway Targeted Cancer Immunotherapy Summit
Apr 05, 2022 7:00am EDT Can-Fite is Developing a Topical Piclidenoson Psoriasis Treatment that Shows Efficacy in a Preclinical Model: Potential Complementary Product to its Phase III Oral Psoriasis Drug
Mar 28, 2022 7:00am EDT Can-Fite to Present at Dermatology Drug Development Summit Europe on April 6, 2022
Mar 14, 2022 7:00am EDT Can-Fite: Namodenoson’s Treatment of Liver Fibrosis Receives Notice of Allowance from U.S. Patent Office
Mar 11, 2022 7:00am EST Can-Fite’s Findings in the Treatment of Liver Diseases with Cannabinoids to be Presented at CannX Medical Cannabis Conference in Tel Aviv
